Men's Essentials Plus
On sale on the US market (according to the DSLD)
Clinical Synergy Professional Formulas, food supplement from the US market
Men's Essentials Plus (Clinical Synergy Professional Formulas), a food supplement au code-barres 892985000478, is described by its US market label. If sold in France, it would be subject to 12 points of French or European regulation, detailed below. Doses of folates, niacine, vitamine A are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine C: up to 1,000 mg a day according to the label (at most 2 servings a day), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Vitamine D: up to 25 µg a day according to the label (at most 2 servings a day), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 22 mg a day according to the label (at most 2 servings a day), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Iode: up to 250 µg a day according to the label (at most 2 servings a day), above the maximum dose of 150 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Sélénium: up to 100 µg a day according to the label (at most 2 servings a day), above the maximum dose of 50 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Chrome: up to 120 µg a day according to the label (at most 2 servings a day), above the maximum dose of 25 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Molybdène: up to 75,000 µg a day according to the label (at most 2 servings a day), above the maximum dose of 150 µg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- À vérifier
Vitamine B6: up to 22 mg a day according to the label, above the tolerable upper intake level from EFSAEuropean Food Safety Authority. for adults (12 mg a day). The EFSA reference covers total daily intake, from food and supplements.
Source: EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), limite supérieure de sécurité (UL).
- À vérifier
Molybdène: up to 75 mg a day according to the label, above the tolerable upper intake level from EFSA for adults (0.6 mg a day). The EFSA reference covers total daily intake, from food and supplements.
Source: EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), limite supérieure de sécurité (UL).
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Turnera diffusa Willd. ex Schult.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Prunus africana (Hook. f.) Kalkman: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Urtica dioica L.: L'étiquetage des compléments alimentaires contenant les parties souterraines de cette plante doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Clinical Synergy Professional Formulas
- Barcode
- 892985000478
- Form
- Capsule
- One serving
- 3 capsules
- Servings
- up to 2 servings per day
- Other ingredients (in English, as written)
- Vegetable Capsule, Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin A | Vitamin | 2,500 UI |
| Vitamin C | Vitamin | 500 mg |
| Vitamin D3 | Vitamin | 500 UI |
| Vitamin E | Vitamin | 20 UI |
| Thiamine | Vitamin | 2.5 mg |
| Niacin | Vitamin | 25 mg |
| Vitamin B6 | Vitamin | 11 mg |
| Folate | Vitamin | 200 µg |
| Vitamin B12 | Vitamin | 30 µg |
| Biotin | Vitamin | 150 µg |
| Pantothenic Acid | Vitamin | 15 mg |
| Calcium | Mineral | 24 mg |
| Iodine | Mineral | 125 µg |
| Magnesium | Mineral | 60 mg |
| Zinc | Mineral | 7.5 mg |
| Selenium | Mineral | 50 µg |
| Copper | Mineral | 1 mg |
| Chromium | Mineral | 60 µg |
| Molybdenum | Mineral | 37.5 mg |
| Potassium | Mineral | 15 µg |
| Detox and Liver Support Blend | Blend | 102.5 mg |
| Glycine | Amino acid | not stated |
| Taurine | Other substance | not stated |
| Broccoli (Brassica oleracea) | Plant | not stated |
| Milk Thistle Extract (Silybum marianum) | Plant | not stated |
| Turmeric root extract (Curcuma longa) | Plant | not stated |
| Oregon Grape | Plant | not stated |
| Grape Seed Extract | Plant | not stated |
| L-Glutathione | Other substance | not stated |
| Alpha Lipoic Acid | Other substance | 37.5 mg |
| Vitality, Metabolic and Endocrine Support Blend | Blend | 57.5 mg |
| Choline | Vitamin | not stated |
| Lecithin | Fat | not stated |
| Acetyl-L-Carnitine | Other substance | not stated |
| DMAE | Other substance | not stated |
| Ginkgo leaf extract | Plant | not stated |
| Ginseng (Panax ginseng) | Plant | not stated |
| Mixed Tocopherols | Vitamin | 40 mg |
| Prostate and Endocrine Support Blend | Blend | 26.25 mg |
| Saw Palmetto extract (Serenoa repens) | Plant | not stated |
| Oat Straw extract (Avena sativa) | Plant | not stated |
| Damiana (Turnera diffusa) | Plant | not stated |
| Pumpkin (Cucurbita pepo) | Plant | not stated |
| Pygeum (Prunus africana) | Plant | not stated |
| Stinging Nettle (Urtica dioica) | Plant | not stated |
| Lycopene | Other substance | not stated |
| Antioxidant Blend | Blend | 24 mg |
| Quercetin | Other substance | not stated |
| Hesperidin | Other substance | not stated |
| Bilberry fruit extract | Plant | not stated |
| Lutein | Other substance | not stated |
| Citrus Bioflavonoid Complex | Other substance | not stated |
| Inositol | Other substance | 20 mg |
| Boron | Mineral | 1 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Men's Essentials Plus
Entered into DSLD on 22 January 2021. Withdrawn from the US market on 22 December 2021 (according to the DSLD).- Active ingredient added : Riboflavin (5 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vitamin D3
Read the warning, when it applies and the studies cited
VITAMIN D (>1,000 - 2,500 IU)
Route of administration: Oral
Cautions and warnings
Condition of application: All products except products containing zinc sourced from picolinate requiring a contraindication.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).
Sources cited by Health Canada (2)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).
Sources cited by Health Canada (3)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
- DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.
Applies to products containing vitamin K2.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).
Sources cited by Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Applies to products providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).
Sources cited by Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Contraindications
Condition of application: All products.
Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).
Sources cited by Health Canada (2)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Applies to products containing zinc sourced from picolinate.
Do not use if you are pregnant or breastfeeding (NNHPD 2026).
Sources cited by Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
Known adverse reactions
Condition of application: All products.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).
Sources cited by Health Canada (2)
- BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
- NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
Applies to products providing more than 350 mg of magnesium per day.
When using this product you may experience diarrhea (NNHPD 2026).
Sources cited by Health Canada (2)
- NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
- DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre
- Taurine
Read the warning, when it applies and the studies cited
TAURINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Lopez Ramon et al. 2007; Seghieri et al. 2007).
Sources cited by Health Canada (2)
- López Ramón Y Cajal C, Ocampo Martínez R, Couceiro Naveira E, Martínez M. Amino acids in amniotic fluid in the 15th-16th weeks of gestation and preterm labor. The Journal of Maternal-Fetal & Neonatal Medicine: the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2007;20(3):225-231.
- Seghieri G, Tesi F, Bianchi L, Loizzo A, Saccomanni G, Ghirlanda G, Anichini R, Franconi F. Taurine in women with a history of gestational diabetes. Diabetes Research and Clinical Practice 2007;76(2):187-192. PubMed
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Milk Thistle Extract
Read the warning, when it applies and the studies cited
MILK THISTLE - SILYBUM MARIANUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Sources cited by Health Canada (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
- Turmeric root extract
Read the warning, when it applies and the studies cited
TURMERIC - CURCUMA LONGA - Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
Sources cited by Health Canada (2)
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
Sources cited by Health Canada (6)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 26 September 2025
Turmeric -CURCUMA LONGA - Topical
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
- Ginseng
Read the warning, when it applies and the studies cited
PANAX GINSENG
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Clinical trial
- Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).
Sources cited by Health Canada (8)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
- Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Case report
- Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
- Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Case report
- Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Randomised trial
- Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Case report
- Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Case report
Contraindications
Condition of application: Traditional Chinese Medicine.
Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).
Sources cited by Health Canada (1)
- Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
Known adverse reactions
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).
Sources cited by Health Canada (8)
- Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Systematic review
- de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
- Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Randomised trial
- Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Randomised trial
- Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
- Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
- Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
- Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Saw Palmetto extract
Read the warning, when it applies and the studies cited
SAW PALMETTO – SERENOA REPENS
Route of administration: Oral
Cautions and warnings
Condition of application: All subpopulations.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Adult males only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.
Condition of application: Adult females only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
Contraindications
Condition of application: Adult females only.
Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
- Pygeum
Read the warning, when it applies and the studies cited
PYGEUM - PRUNUS AFRICANA
Route of administration: Oral
Cautions and warnings
Condition of application: Standardized extracts making a claim for symptoms of benign prostatic hyperplasia (adult males).
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (Goldman and Ausiello 2004).
Sources cited by Health Canada (1)
- Goldman L, Ausiello D. Cecil Textbook of Medicine. 22nd edition. Philadelphia (PA): Saunders; 2004.
Condition of application: Non-standardized preparations for adults (i.e., including women) (safety only).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
- Stinging Nettle
Read the warning, when it applies and the studies cited
STINGING NETTLE JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products except nutritive tonics.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.
Known adverse reactions
Condition of application: All products except those making only a diuretic claim*.
When using this product diuretic effect may occur.
*Note: This statement can be removed from the label if a diuretic claim is included.
Health Canada monograph dated 27 March 2026
STINGING NETTLE - URTICA DIOICA
Route of administration: Oral
Cautions and warnings
Condition of application: All products except nutritive tonics.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.
Known adverse reactions
All products except those making only a diuretic claim*
When using this product diuretic effect may occur.
*Note: This statement can be removed from the label if a diuretic claim is included.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Clinical Synergy Professional Formulas
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Men's Essentials Plus (Clinical Synergy Professional Formulas): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/892985000478-men-s-essentials-plus-clinical-synergy-professional-formulas, updated 23 April 2020.